Johnson & Johnson uses the prospect of jail time to market a schizophrenia drug

Quick Read

Drugmakers gave millions of dollars to pain-treatment advocacy groups over a five-year period beginning in 2012, in effect promoting opioids to individuals most vulnerable to addiction, according to a new report released Monday by a U.S. senator

Quick Read

Dozens of doctors, medical ethicists, and lawyers are warning Congress that legislation to allow Americans with life-threatening conditions access to unapproved, experimental drugs risks harming patients’ health

Quick Read

It’s a disaster in the making…it’s actually an approach that could do more harm than good for people who seemingly have “nothing left to lose.” I’m also not sure why such a law is needed, since people like me already have access to experimental therapies

Quick Read

Christopher Robertson and Kelly McBride Folkers write, “Despite the policy’s broad support, it has yet to help a single patient in Arizona obtain an experimental drug that they couldn’t have gotten before. Thirty-seven other states have also passed right to try bills, but likewise have seen little real impact for patients.”

Quick Read

Pfizer, one of the world’s largest drug companies, announced over the weekend that it would stop work on new drugs to fight Alzheimer’s disease and Parkinson’s disease. The reason? Pfizer believes that research on the two diseases doesn’t make sense financially

Quick Read

Renda Bower knows well the cost of drugs to treat rheumatoid arthritis – her husband, son and daughter all have the painful, disabling autoimmune disease. And the family’s finances revolve around paying for them

Quick Read

Facing bipartisan hostility over high drug prices in an election year, the pharma industry’s biggest trade group boosted revenue by nearly a fourth last year and spread the millions collected among hundreds of lobbyists, politicians and patient groups, new filings show

Quick Read